Sources Say Amgen Plans To Sell Biotech Japanese Unit (Japan)
This article was originally published in PharmAsia News
Executive Summary
The world's largest biotechnology company, Amgen plans cost reductions, beginning by closing its Japan unit, according to sources. U.S.-based Amgen is suffering a decline in sales and is asking $403 million for its Tokyo operation, beginning the talks with Japanese drugmakers. A spokeswoman called the reports "speculation." The Japan unit develops biotech treatments for asthma, cancer and rheumatoid arthritis in Japan. (Click here for more